Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 3147Triple Negative Breast Neoplasms 515Ovarian Neoplasms 230Colorectal Neoplasms 192Carcinoma, Non-Small-Cell Lung 190Prostatic Neoplasms 184Neoplasms 177Lung Neoplasms 165Neoplasm Metastasis 164Melanoma 119Stomach Neoplasms 114Pancreatic Neoplasms 113Endometrial Neoplasms 107Uterine Cervical Neoplasms 95Squamous Cell Carcinoma of Head and Neck 88Head and Neck Neoplasms 82Colonic Neoplasms 82Carcinoma, Intraductal, Noninfiltrating 82Sarcoma 63Breast Carcinoma In Situ 62Carcinoma, Renal Cell 61Urinary Bladder Neoplasms 60Motor Activity 59Esophageal Neoplasms 58Brain Neoplasms 50Lymphedema 44Breast Cancer Female 41Advanced Breast Cancer 40Liver Neoplasms 39HER2-positive Breast Cancer 38

Interventions

trastuzumab deruxtecan 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unresectable Locally Recurrent Breast Cancer × Breast × 1 year × Clear all
NCT07497386 2026-05-11

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Recruiting
150 enrolled
Breast

Unresectable Locally Recurrent Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡